National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Liver Diseases Branch, Bethesda, Maryland.
National Cancer Institute (NCI), Experimental Transplantation and Immunology Branch, Bethesda, Maryland.
Transplant Cell Ther. 2022 Nov;28(11):747.e1-747.e10. doi: 10.1016/j.jtct.2022.07.017. Epub 2022 Jul 22.
Hepatic chronic graft-versus-host disease (cGVHD) causes morbidity and current diagnostic criteria are nonspecific. An accurate diagnosis is imperative because overdiagnosis can lead to unnecessary treatment with immunosuppressive agents and raising the risk of opportunistic infections. We aim to characterize different patterns of liver injury and cytokine profiles associated with hepatic dysfunction in cGVHD, to evaluate the accuracy of the NIH Consensus Criteria (NCC) for hepatic cGVHD and to explore predictors for hepatic cGHVD. Patients were evaluated in this prospective cross-sectional study of patients with cGVHD recruited under a natural history protocol. Laboratory tests and cytokines were measured. The cGVHD were diagnosed and scored based on NCC. Clinically indicated liver biopsy specimens or autopsies were reviewed by an expert hepatopathologist (D.E.K.). Comparisons were made between groups, and univariable and multivariable logistic regression were calculated. Of the 302 patients enrolled, 151 fulfilled hepatic cGVHD based on NCC; however, 69% had at least 1 abnormal liver test result. Abnormal alanine aminotransferase (ALT) and aspartate aminotransferase were associated with lower platelets, higher total bilirubin (TB), total cholesterol, serum amyloid A, and IL 15. Abnormal ALP and gamma-glutamyl transpeptidase were associated with higher cholesterol, and IL7. Lower platelet count was associated with higher ALT, TB, and triglycerides and lower albumin. Of the 27 with liver tissue, 16 had histologic features of GVHD, only eight met clinical criteria for hepatic GVHD. Sensitivity and specificity of NCC in identifying hepatic GVHD were 50% and 27% (Kappa = -0.23). Only 6 had only hepatic GVHD, whereas 10 had hepatic GVHD with either iron overload, nodular regenerative hyperplasia, or steatosis. Multivariable logistic regression showed that ALP and total cholesterol were associated with hepatic GVHD and total cholesterol >220 mg/dL increased the sensitivity for histologic hepatic GVHD. In conclusion, abnormal liver enzymes in cGVHD are nonspecific and have poor correlation with histologic evidence for hepatic GVHD, highlighting the importance of histology. Cytokines provide insight into the pathogenesis of hepatic cGVHD. Decreased platelet count was associated with factors associated with liver disease including portal vein diameter, which may suggest progression of liver disease. This highlights the need of incorporating these factors in natural history study and using liver biopsy to understand the development of liver dysfunction in hematopoietic stem cell transplantation and to develop better instruments to decreased hepatic cGVHD related morbidity and mortality. The study was registered with a ClinicalTrials.gov identifier NCT00092235.
肝慢性移植物抗宿主病(cGVHD)可导致发病,目前的诊断标准不具有特异性。准确的诊断至关重要,因为过度诊断可能导致不必要的免疫抑制治疗,并增加机会性感染的风险。我们旨在描述与 cGVHD 相关的肝损伤和细胞因子谱的不同模式,评估 NIH 共识标准(NCC)对肝 cGVHD 的准确性,并探讨肝 cGHVD 的预测因素。
在这项前瞻性 cGVHD 患者的横断面研究中,根据自然史方案招募了患者。进行了实验室检查和细胞因子测量。根据 NCC 诊断和评分 cGVHD。由一位专家肝病学家(D.E.K.)对临床指征的肝活检标本或尸检进行评估。对组间进行了比较,并计算了单变量和多变量逻辑回归。
在纳入的 302 例患者中,根据 NCC,有 151 例符合肝 cGVHD;然而,69%的患者至少有 1 项肝功能异常。异常丙氨酸氨基转移酶(ALT)和天冬氨酸氨基转移酶与血小板减少、总胆红素(TB)、总胆固醇、血清淀粉样蛋白 A 和 IL15 升高有关。异常碱性磷酸酶(ALP)和γ-谷氨酰转肽酶与胆固醇和 IL7 升高有关。血小板计数降低与 ALT、TB 和甘油三酯升高以及白蛋白降低有关。在 27 例有肝组织的患者中,16 例有 GVHD 的组织学特征,仅 8 例符合肝 GVHD 的临床标准。NCC 识别肝 GVHD 的敏感性和特异性分别为 50%和 27%(Kappa=-0.23)。只有 6 例仅有肝 GVHD,而 10 例既有肝 GVHD,又有铁过载、结节性再生性增生或脂肪变性。多变量逻辑回归显示,ALP 和总胆固醇与肝 GVHD 相关,总胆固醇>220mg/dL 增加了肝组织学 GVHD 的敏感性。
总之,cGVHD 中的异常肝酶不具有特异性,与肝 GVHD 的组织学证据相关性差,突出了组织学的重要性。细胞因子提供了对肝 cGVHD 发病机制的深入了解。血小板计数降低与包括门静脉直径在内的与肝病相关的因素有关,这可能表明肝病的进展。这突出表明需要在自然史研究中纳入这些因素,并使用肝活检来了解造血干细胞移植中肝功能障碍的发展,并开发更好的工具来降低肝 cGVHD 相关发病率和死亡率。该研究在 ClinicalTrials.gov 注册,标识符为 NCT00092235。